Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 2, 2023JAC-Antimicrobial ResistanceOpen Access

Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019–21)

View Full Paper
Ask AI
Bookmark
Share

Authors

HSHélio S. SaderMCMariana CastanheiraJKJohn H. Kimbrough

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Sader et al. (2023) studied this question.

synapsesocial.com/papers/6a723cc18031ec7bb1dd4a17https://doi.org/10.1093/jacamr/dlad032
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase–Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies2022 · 111 citations
  2. 2The Clinical and Molecular Epidemiology of Noncarbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae: A Case-Case-Control Matched Analysis2020 · 41 citations
  3. 3Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review2021 · 101 citations
  4. 4<i>In Vitro</i> Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 20152017 · 193 citations
  5. 5Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing <i>Enterobacterales</i> in the Antibiotic Resistance Laboratory Network, March 2019 to December 20202021 · 30 citations